Living Cell Technologies Limited
Algorae Pharmaceuticals Limited, a pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate made up of donepezil and cannabidiol for the treatment of dementia, including Alzheimer's disease; AI-168, a novel combination drug candidate made up … Read more
Living Cell Technologies Limited (LVCLF) - Total Liabilities
Latest total liabilities as of June 2025: $169.76K USD
Based on the latest financial reports, Living Cell Technologies Limited (LVCLF) has total liabilities worth $169.76K USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Living Cell Technologies Limited - Total Liabilities Trend (2004–2025)
This chart illustrates how Living Cell Technologies Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Living Cell Technologies Limited Competitors by Total Liabilities
The table below lists competitors of Living Cell Technologies Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kumpulan H & L High-Tech Bhd
KLSE:7033
|
Malaysia | RM37.63 Million |
|
MainStreetChamber Holdings Inc.
PINK:MSCH
|
USA | $94.38K |
|
EPS Bio Technology Corp.
TWO:4183
|
Taiwan | NT$237.34 Million |
|
Fresh Grapes LLC
NYSE MKT:VINE
|
USA | $2.93 Million |
|
AB Panevezio Statybos Trestas
STU:YK3
|
Germany | €57.08 Million |
|
Forza Land Indonesia Tbk PT
JK:FORZ
|
Indonesia | Rp305.17 Billion |
|
PP PRIME Public Company Limited
BK:PPPM
|
Thailand | ฿345.65 Million |
Liability Composition Analysis (2004–2025)
This chart breaks down Living Cell Technologies Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Living Cell Technologies Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Living Cell Technologies Limited (2004–2025)
The table below shows the annual total liabilities of Living Cell Technologies Limited from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $169.76K | -4.87% |
| 2024-06-30 | $178.45K | -60.33% |
| 2023-06-30 | $449.86K | +88.02% |
| 2022-06-30 | $239.26K | -9.74% |
| 2021-06-30 | $265.08K | -48.30% |
| 2020-06-30 | $512.72K | -68.37% |
| 2019-06-30 | $1.62 Million | +242.39% |
| 2018-06-30 | $473.47K | -59.74% |
| 2017-06-30 | $1.18 Million | +84.97% |
| 2016-06-30 | $635.80K | +88.30% |
| 2015-06-30 | $337.65K | -72.62% |
| 2014-06-30 | $1.23 Million | +27.64% |
| 2013-06-30 | $966.00K | -17.44% |
| 2012-06-30 | $1.17 Million | +64.47% |
| 2011-06-30 | $711.40K | +1.09% |
| 2010-06-30 | $703.74K | -27.65% |
| 2009-06-30 | $972.64K | +36.19% |
| 2008-06-30 | $714.19K | -70.44% |
| 2007-06-30 | $2.42 Million | -3.91% |
| 2006-06-30 | $2.51 Million | +210.76% |
| 2005-06-30 | $809.16K | -69.29% |
| 2004-06-30 | $2.63 Million | -- |